AUTHORS
Huiqiang Huang, MD, PhD, Gao Yan, PhD2, Xuan-Ye Zhang3, Jicheng Hong4, Jingwen Wang5, Jia-Ling Zhuang6, jiaowu Cao7, Xiujin Chen8
AFFILIATIONS
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Sun Yat-sen University Cancer Center, Guangzhou, China
5 Sun Yat-sen University Cancer Center, Guangzhou, China
6 Sun Yat-sen University Cancer Center, Guangzhou, China
7 Sun Yat-sen University Cancer Center, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China
ABSTRACT
Background
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge with poor outcomes following standard immunochemotherapy. Novel immunotherapies such as CAR-T and bispecific antibodies are effective but not universally accessible or durable. Combining Tislelizumab (anti-PD-1 antibody) with immunomodulation represents a promising chemotherapy-free strategy. The purpose of this phase II trial is to evaluate the efficacy and toxicity of tislelizumab plus lenalidomide in elderly R/R DLBCL (NCT04796857).
Method
This single-center, open-label, single-arm study enrolled adult R/R DLBCL patients at Sun Yat-sen University Cancer Center between February 2021 and April 2026. Patients received tislelizumab 200 mg IV Q3W plus lenalidomide 20 mg PO on days 1–21 of each 28-day cycle until progression, unacceptable toxicity, or withdrawal. The primary endpoint was objective response rate (ORR) and complete response rate (CRR) per Lugano 2014 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and duration of response (DOR), estimated by Kaplan–Meier. Safety was graded per CTCAE v5.0.
Result
Of 30 enrolled patients, 26 were efficacy-evaluable (4 discontinued prior to first restaging). Median age was 71.0 years (range, 56–84); 65.4% had stage III–IV disease; 57.7% received ≥2 prior lines (median, 2; range, 1–3); and 65.4% had non-GCB subtype by Hans classification. Among the 26 efficacy-evaluable patients, The ORR was 53.8%(14/26), with a CRR of 38.5%(10/26). ORR was 33.3% (3/9) in GCB versus 64.7% (11/17) in non-GCB. At a median follow-up of 47.6 months (range, 0.9–61.4), 13 deaths were documented, of which 12 were attributed to disease progression and 1 to a cardiovascular event. The median OS was 32.9 months (95% CI, 17.5–NA), and the median PFS was 5.5 months (95% CI, 3.3–20.8). The estimated 1-, 2-, and 3-year OS rates were 72.7% (56.3%-93.9%), 54.5% (37.2%-79.9%), and 43.6% (26.7%-71.3%), respectively. The 1-, 2-, and 3-year PFS rates were 34.6% (20.4%-58.7%), 23.1% (11.4%-46.6%), 23.1% (11.4%-46.6%), respectively. Among 14 responders, 11 experienced disease progression; the median DOR was 16.5 months (95% CI, 6.2–NA). The most common TRAEs were rash, pruritus, hematologic toxicities, pyrexia, hypothyroidism, pneumonitis, and other immune-related adverse events, predominantly grade 1–2. One patient developed grade 4 hepatitis, which was considered immune-related and resolved with corticosteroid therapy; the patient subsequently discontinued study treatment. No treatment-related deaths occurred.
Conclusion
Tislelizumab plus lenalidomide demonstrated meaningful antitumor activity with a manageable safety profile in heavily pretreated elderly R/R DLBCL, although median PFS was modest. The durable responses observed in a subset of patients and the encouraging OS support this chemo-free regimen as a potential bridge to definitive therapy and warrant further biomarker-driven investigation.
DISCLOSURES
Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.